Edition:
United Kingdom

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

8.45USD
13 Dec 2017
Change (% chg)

$0.55 (+6.96%)
Prev Close
$7.90
Open
$7.95
Day's High
$8.45
Day's Low
$7.95
Volume
155,218
Avg. Vol
168,657
52-wk High
$17.20
52-wk Low
$7.00

Select another date:

Tue, Nov 21 2017

Cytokinetics sinks on abandoning ALS drug after failed trial

Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.

UPDATE 4-Cytokinetics sinks on abandoning ALS drug after failed trial

Nov 21 Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.

BRIEF-Cytokinetics Inc announces negative results from VITALITY-ALS

* Phase 3 clinical trial of Tirasemtiv in patients with ALS did not meet primary or secondary endpoints​

Cytokinetics' neuro-degenerative drug fails late-stage trial

Nov 21 Cytokinetics Inc said on Tuesday its drug to treat a type of neuro-degenerative disorder failed to meet the main goal of a late-stage trial.

BRIEF-Cytokinetics files for potential mixed shelf, size undisclosed‍​

* Cytokinetics Inc files for potential mixed shelf, size undisclosed - SEC Filing ‍​ Source text: http://bit.ly/2hauCBo Further company coverage:

BRIEF-Cytokinetics enters into second amendment to certain loan and security agreement

* Cytokinetics - ‍on Oct 27, entered into second amendment to certain loan and security agreement dated as of October 19, 2015

BRIEF-Cytokinetics reports Q3 loss of ‍$0.60/shr​

* Cytokinetics, Inc. reports third quarter 2017 financial results

BRIEF-Cytokinetics announces dosing of first patient in Japan in phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure

* Cytokinetics announces dosing of first patient in Japan in GALACTIC-HF, phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure

BRIEF-Cytokinetics announces additional results from COSMIC-HF at HFSA 21st Annual Scientific Meeting

* Cytokinetics announces presentation of additional results from COSMIC-HF at the HFSA 21st Annual Scientific Meeting Source text for Eikon: Further company coverage:

BRIEF-Cytokinetics Q2 loss per share $0.60

* Cytokinetics Inc reports second quarter 2017 financial results

Select another date: